Match!

Predictive and Prognostic Survival Factors in Peritoneal Carcinomatosis from Appendiceal Cancer After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Published on Dec 1, 2014in Annals of Surgical Oncology3.681
· DOI :10.1245/s10434-014-3869-1
William Andres Jimenez6
Estimated H-index: 6
(Mercy Medical Center (Baltimore, Maryland)),
Armando Sardi25
Estimated H-index: 25
(Mercy Medical Center (Baltimore, Maryland))
+ 5 AuthorsVadim Gushchin14
Estimated H-index: 14
(Mercy Medical Center (Baltimore, Maryland))
Abstract
Background Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has survival benefit in the treatment of selected patients with peritoneal carcinomatosis (PC) from appendiceal cancer (AC). We evaluated factors affecting the survival of patients with PC from AC after CRS/HIPEC.
  • References (44)
  • Citations (24)
📖 Papers frequently viewed together
470 Citations
665 Citations
396 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References44
Newest
#1Edward A. Levine (Wake Forest University)H-Index: 54
#2John H. Stewart (Wake Forest University)H-Index: 30
Last. Konstantinos I. Votanopoulos (Wake Forest University)H-Index: 21
view all 6 authors...
Background Peritoneal dissemination of abdominal malignancy (carcinomatosis) has a clinical course marked by bowel obstruction and death; it traditionally does not respond well to systemic therapy and has been approached with nihilism. To treat carcinomatosis, we use cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Methods A prospective database of patients has been maintained since 1992. Patients with biopsy-proven peritoneal surface disease were uniformly eval...
117 CitationsSource
#1Mehraneh D. Jafari (UCI: University of California, Irvine)H-Index: 13
#2Wissam J. Halabi (UCI: University of California, Irvine)H-Index: 18
Last. Alessio Pigazzi (UCI: University of California, Irvine)H-Index: 39
view all 7 authors...
Importance Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have been shown to benefit selected patients with peritoneal carcinomatosis. However, these procedures are associated with high morbidity and mortality. Available data investigating the outcomes of HIPEC are mostly limited to single-center studies. To date, there have been few large-scale studies investigating the postoperative outcomes of HIPEC. Objective To determine the associated 30-day morbidity and morta...
54 CitationsSource
#1Bernhard Klumpp (University of Tübingen)H-Index: 16
#2Philip AschoffH-Index: 18
Last. Christina PfannenbergH-Index: 34
view all 9 authors...
Purpose: In patients with peritoneal carcinomatosis, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is an evolving approach with curative intention. Previous studies indicate a correlation between preoperative magnetic resonance imaging (MRI) and surgical findings regarding the extent of peritoneal carcinomatosis. The aim of this study was to assess retrospectively whether preoperative MRI can predict the outcome and is therefore a suitable tool for patient sel...
11 CitationsSource
BACKGROUND:Pseudomyxoma peritonei is a diffuse peritoneal malignancy that generally originates form a perforated appendiceal tumor. Optimal treatment requires extensive surgical resection to achieve complete cytoreduction combined with hyperthermic intraperitoneal chemotherapy. In a proportion of pa
36 CitationsSource
#1Armando Sardi (Mercy Medical Center (Baltimore, Maryland))H-Index: 25
#2William Andres Jimenez (Mercy Medical Center (Baltimore, Maryland))H-Index: 6
Last. Vadim Gushchin (Mercy Medical Center (Baltimore, Maryland))H-Index: 14
view all 6 authors...
Abstract Background Cytoreductive surgery (CRS)/hyperthermic intraperitoneal chemotherapy (HIPEC) is the procedure of choice in patients with peritoneal dissemination from appendiceal cancer. Although recurrence rates are 26%–44% after first CRS/HIPEC, the role of repeated CRS/HIPEC has not been well defined. We hypothesize that patients undergoing multiple CRS/HIPEC's have meaningful long term survival. Methods A retrospective study of a prospective database of 294 patients with peritoneal carc...
20 CitationsSource
#1A. Kuijpers (NKI-AVL: Netherlands Cancer Institute)H-Index: 6
#2Boj Mirck (NKI-AVL: Netherlands Cancer Institute)H-Index: 1
Last. Vic J. Verwaal (NKI-AVL: Netherlands Cancer Institute)H-Index: 29
view all 13 authors...
Purpose This nationwide study evaluated results of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis of colorectal origin in the Netherlands following a national protocol.
110 CitationsSource
#1L. H. Iversen (Aarhus University Hospital)H-Index: 5
#2P. C. Rasmussen (Aarhus University Hospital)H-Index: 5
Last. Søren Laurberg (Aarhus University Hospital)H-Index: 60
view all 4 authors...
Aim Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option with curative intent for selected patients with peritoneal carcinomatosis (PC). CRS and HIPEC have been implemented in Denmark at a single centre since 2006. Six years of data on these patients were analysed. Method Patients with PC from colorectal or appendiceal cancer, pseudomyxoma peritonei or malignant peritoneal mesothelioma referred to the single national HIPEC centre were ...
17 CitationsSource
Background Pseudomyxoma peritonei (PMP) is a rare disease with an incidence rate of approximately 1 per million a year. During the past few years, there has been a survival benefit for these patients treated by complete cytoreduction and perioperative chemotherapy. Better survival rates were found in the adenomucinosis group than the carcinomatosis group. The purpose of our study was to analyze the outcome and the prognosis factors of only high-grade PMP.
13 CitationsSource
#1Melissa Ching Ching Teo (SGH: Singapore General Hospital)H-Index: 13
#2Grace Hwei Ching Tan (SGH: Singapore General Hospital)H-Index: 8
Last. Khee Chee SooH-Index: 42
view all 5 authors...
Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival in selected patients with peritoneal carcinomatosis. We review our institutional experience with the procedure and evaluate the overall survival (OS) and disease-free survival (DFS) rates in 100 consecutive patients.
20 CitationsSource
#1Russell N. LowH-Index: 21
#2Robert M. Barone (Sharp Memorial Hospital)H-Index: 5
Last. Melissa Lee (UCSD: University of California, San Diego)H-Index: 4
view all 3 authors...
Background The purpose of this study was to determine if MRI surveillance is better than serum tumor makers in detecting early recurrence in patients with mucinous appendiceal neoplasm.
20 CitationsSource
Cited By24
Newest
#1Andrei Nikiforchin (Mercy Medical Center (Baltimore, Maryland))H-Index: 1
#2Vadim Gushchin (Mercy Medical Center (Baltimore, Maryland))H-Index: 14
Last. Armando Sardi (Mercy Medical Center (Baltimore, Maryland))H-Index: 25
view all 4 authors...
Source
#1Andrei NikiforchinH-Index: 1
#2Mary Caitlin KingH-Index: 1
Last. Armando SardiH-Index: 25
view all 8 authors...
BACKGROUND: Low-grade appendiceal mucinous neoplasms (LAMN) are tumors that frequently present with peritoneal spread of either acellular mucin (AM) or cellular mucin (CM). We aim to determine how mucin types and distribution affect survival. PATIENTS AND METHODS: A retrospective cohort study was conducted using a prospective database. Newly diagnosed LAMN patients with AM versus CM treated with cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) were compared. Postoperat...
1 CitationsSource
#1Toshiyuki KitaiH-Index: 20
#2Kenya YamanakaH-Index: 12
view all 4 authors...
Purpose Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is the active treatment for peritoneal carcinomatosis of appendiceal origin. However, surgical management is sometimes difficult in patients with a high-tumor burden.
Source
#1Tiffany C. Lee (UC: University of Cincinnati)H-Index: 1
#2Koffi Wima (UC: University of Cincinnati)H-Index: 14
Last. Sameer H. Patel (UC: University of Cincinnati)H-Index: 14
view all 27 authors...
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) results in significant morbidity and readmissions. Previous studies have been limited by single-institution design or lack of tumor details in the database used. METHODS: The 12-institution US HIPEC Collaborative Database was queried between 1999 and 2017. Preoperative and intraoperative patient and tumor details were analyzed for associations with readmissions. RESULTS: A total of 2017 of 2372 cases were...
5 CitationsSource
#1Katherin Zambrano-Vera (Mercy Medical Center (Baltimore, Maryland))H-Index: 1
#2Armando Sardi (Mercy Medical Center (Baltimore, Maryland))H-Index: 25
Last. Vadim Gushchin (Mercy Medical Center (Baltimore, Maryland))H-Index: 14
view all 9 authors...
Background Appendiceal goblet cell adenocarcinoma (GCA) is often misclassified and mistreated due to mixed histologic features. In general, cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is standard of care for peritoneal carcinomatosis (PC) from mucinous appendiceal tumors; however, in PC from GCA, data are limited and the role of CRS/HIPEC is controversial. We report outcomes in PC from appendiceal GCA treated with CRS/HIPEC.
1 CitationsSource
#1Joel M. Baumgartner (UCSD: University of California, San Diego)H-Index: 14
#2Kaitlyn J. Kelly (UCSD: University of California, San Diego)H-Index: 19
Appendiceal tumors are rare, and there are various subtypes with very different histologic characteristics and biologic behavior. Mucinous appendiceal tumors tend to spread within the peritoneal cavity and lead to the clinical syndrome of pseudomyxoma peritonei (PMP). Because PMP tends to stay confined to the peritoneal cavity, aggressive regional therapy with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been applied to this disease and is currently consi...
Source
#1Xin-Bao Li (Capital Medical University)H-Index: 1
#2Kaiwen Peng (Capital Medical University)
Last. Yan Li (Capital Medical University)H-Index: 16
view all 6 authors...
Background:This study was to assess the risk of venous thromboembolism (VTE) in patients with peritoneal carcinomatosis (PC) and to evaluate the safety and feasibility of physiotherapy program to p...
Source
#1Carlos Munoz-Zuluaga (Mercy Medical Center (Baltimore, Maryland))H-Index: 1
#2Mary Caitlin King (Mercy Medical Center (Baltimore, Maryland))H-Index: 1
Last. Armando Sardi (Mercy Medical Center (Baltimore, Maryland))H-Index: 25
view all 8 authors...
Abstract Background The role of systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in appendiceal high-grade mucinous carcinoma peritonei (HGMCP) is controversial. We analyzed the effect of SC prior to CRS/HIPEC in HGMCP. Methods A prospective database of CRS/HIPEC procedures for HGMCP without signet ring cells and with signet ring cells (HGMCP-S) from 1998 to 2017 was reviewed. Exclusion criteria was prior surgery >5 regions or >2 r...
Source
#1Carlos Munoz-Zuluaga (Mercy Medical Center (Baltimore, Maryland))H-Index: 1
#2Armando Sardi (Mercy Medical Center (Baltimore, Maryland))H-Index: 25
Source
Purpose Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become standard of care for many peritoneal malignancies in selected patients. Nevertheless, this aggressive treatment strategy is associated with significant major morbidity. The aim of the present study is to analyze the re-operation rate and clinical outcome following CRS and HIPEC.
Source